GSK plc (GSK) on Thursday said Japan's Ministry of Health, Labour and Welfare has accepted a new drug application for bepirovirsen for the treatment of adults with chronic hepatitis B (CHB).
The submission is supported by positive results from the Phase III B-Well 1 and B-Well 2 trials, in which bepirovirsen demonstrated a statistically significant and clinically meaningful functional cure rate. The drug candidate also showed an acceptable safety and tolerability profile consistent with previous studies.
Chronic hepatitis B affects more than 250 million people globally and nearly one million people in Japan.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.